Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases. Its lead program is MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1), currently in a Phase II clinical trial for APOL1 kidney disease. Another key program is MZE782, an oral small molecule inhibitor that is Phase II ready for phenylketonuria and chronic kidney disease. Additionally, Maze is developing MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase for Pompe disease. The company also has a license agreement with Trace Neuroscience targeting UNC13A, and collaborations with Shionogi & Co. for MZE001 and Neurocrine Biosciences for a program targeting ATXN2.

Maze Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol MAZE. The stock trades in US Dollars (USD), as the company is based in the United States. NasdaqGM is a US-based exchange, so all trading and financial reporting are conducted in USD. Investors can buy and sell shares of MAZE through brokerage accounts that have access to US stock markets.

Maze Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing innovative small molecule precision medicines. Biotechnology companies like Maze use biological processes and molecular biology to create therapies for diseases. In Maze's case, the focus is on kidney and metabolic diseases, including APOL1 kidney disease, phenylketonuria, chronic kidney disease, and Pompe disease. The company's work involves extensive research and clinical trials to bring new treatments to patients.

Maze Therapeutics is headquartered in South San Francisco, California, United States. The company was originally founded in 2017 under the name Modulus Therapeutics, Inc. It rebranded to Maze Therapeutics, Inc. in September 2018. The company operates primarily in the United States, focusing on developing precision medicines for kidney and metabolic diseases. Its location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent, research institutions, and potential partners.

Maze Therapeutics has a pipeline of small molecule precision medicines. Its lead program, MZE829, targets APOL1 and is in Phase II for APOL1 kidney disease. MZE782 is Phase II ready for phenylketonuria and chronic kidney disease. MZE001 is an investigational therapy for Pompe disease. The company also has a license agreement with Trace Neuroscience to discover research targeting UNC13A. Additionally, Maze has partnerships with Shionogi & Co. to research, develop, manufacture, and commercialize MZE001, and with Neurocrine Biosciences to discover a program targeting ATXN2. These collaborations help advance Maze's pipeline and expand its reach.